# Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

> **NCT02282020** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 266 (actual)

## Conditions studied

- Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

## Interventions

- **DRUG:** OLAPARIB
- **DRUG:** Single agent chemotherapy

## Key facts

- **NCT ID:** NCT02282020
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-06
- **Primary completion:** 2018-10-10
- **Final completion:** 2022-07-19
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2022-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02282020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02282020, "Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02282020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*